These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 2697403

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
    Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B.
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):35-8. PubMed ID: 1780750
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
    Lee SS, Lee JH, Lee JH, Kim DY, Kim SH, Lim SN, Lee YS, Seol M, Ryu SG, Kang YA, Jang S, Park CJ, Chi HS, Yun SC, Lee KH.
    Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of poor prognosis acute myeloid leukemia with aggressive and non-aggressive chemotherapy.
    Stenke L, Hast R, Reizenstein P.
    Chemioterapia; 1987 Jun; 6(2 Suppl):723-4. PubMed ID: 3509530
    [No Abstract] [Full Text] [Related]

  • 8. [Chemotherapy of relapsed AML and ALL].
    Nishikawa K.
    Rinsho Ketsueki; 1996 Aug; 37(8):647-50. PubMed ID: 8827871
    [No Abstract] [Full Text] [Related]

  • 9. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A, Polish Adult Leukemia Group.
    Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F, Catovsky D, Slocombe G, Newland AC, Marcus RE, Goldman JM, Galton DA.
    Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
    [Abstract] [Full Text] [Related]

  • 13. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
    Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, Ryu SG, Jang S, Park CJ, Chi HS, Lee JS, Kim WK, Lee KH.
    Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
    [Abstract] [Full Text] [Related]

  • 14. [Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
    Evensen SA, Brinch L, Wisløff F.
    Tidsskr Nor Laegeforen; 1989 Jun 30; 109(19-21):2004-6. PubMed ID: 2749689
    [Abstract] [Full Text] [Related]

  • 15. Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
    van der Jagt RH.
    Leuk Res; 2010 Jul 30; 34(7):856-7. PubMed ID: 20378170
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
    Mariańska B, Apel D, Seferyńska I, Maj S.
    Wiad Lek; 1998 Jul 30; 51(1-2):42-5. PubMed ID: 9608830
    [Abstract] [Full Text] [Related]

  • 18. Mitoxantrone.
    Med Lett Drugs Ther; 1988 Jul 01; 30(769):67-8. PubMed ID: 3380059
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.